Chronic myelomonocytic leukemia in younger patients: Molecular and cytogenetic predictors of survival and treatment outcome

Blood Cancer Journal

Volumn 5, Issue 1, 2015, Pages e270-

  Patnaik, M M ^a   Wassie, E A ^a   Padron, E ^b   Onida, F ^c   Itzykson, R ^d   Lasho, T L ^a   Kosmider, O ^e,f   Finke, C M ^a   Hanson, C A ^a   Ketterling, R P ^a   Komrokji, R ^b   Tefferi, A ^a   Solary, E ^g  

^a MAYO CLINIC   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d SAINT LOUIS HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f INSTITUT COCHIN   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARGININE; AZACITIDINE; SERINE; SERINE ARGININE RICH SPLICING FACTOR 2; UNCLASSIFIED DRUG; NUCLEAR PROTEIN; RIBONUCLEOPROTEIN; SRSF2 PROTEIN, HUMAN;

ADDITIONAL SEX COMBS 1 GENE; ADULT; ADVERSE OUTCOME; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL; BONE MARROW; BONE MARROW CELL; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOGENETICS; FEMALE; GENE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; OVERALL SURVIVAL; PREDICTIVE VALUE; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; YOUNG ADULT; DISEASE FREE SURVIVAL; GENETICS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS;

ADULT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; RIBONUCLEOPROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84927745746     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.90     Document Type: Article

References (26)

1. Patnaik MM, Parikh SA, Hanson CA, Tefferi A. Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol 2014; 165: 273-286.
2. Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013; 31: 2428-2436.
3. Patnaik MM, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia 2014; 28: 2206-2212.
4. Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia 2013; 27: 1504-1510.
5. Wassie EA, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. Am J Hematol 2014; 89: 1111-1115.
6. Ades L, Sekeres MA, Wolfromm A, Teichman ML, Tiu RV, Itzykson R et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res 2013; 37: 609-613.
7. Aribi A, Borthakur G, Ravandi F, Shan J, Davisson J, Cortes J et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 2007; 109: 713-717.
8. Braun T, Itzykson R, Renneville A, de Renzis B, Dreyfus F, Laribi K et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood 2011; 118: 3824-3831.
9. Costa R, Abdulhaq H, Haq B, Shadduck RK, Latsko J, Zenati M et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2011; 117: 2690-2696.
10. Fianchi L, Criscuolo M, Breccia M, Maurillo L, Salvi F, Musto P et al. High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leuk Lymphoma 2013; 54: 658-661.
11. Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T. Macbeth KJ, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 2011; 29: 2521-2527.
12. Thorpe M, Montalvao A, Pierdomenico F, Moita F, Almeida A. Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review. Leuk Res 2012; 36: 1071-1073.
13. Eissa H, Gooley TA, Sorror ML, Nguyen F, Scott BL, Doney K et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant 2011; 17: 908-915.
14. Park S, Labopin M, Yakoub-Agha I, Delaunay J, Dhedin N, Deconinck E et al. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Eur J Haematol 2013; 90: 355-364.
15. Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clinic Proc 2012; 87: 25-33.
16. Swederlow S, Camp E, Harris NL, Jaffe ES, Stefano PA, Stein H et al. (ed) WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer: Lyon, France, 2008.
17. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840-849.
18. Laborde R, Patnaik M, Lasho T, Finke C, Hanson C, Knudson R et al. SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. Leukemia 2013; 27: 2100-2102.
19. Lasho TL, Jimma T, Finke CM, Patnaik M, Hanson CA, Ketterling RP et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood 2012; 120: 4168-4171.
20. Patnaik MM, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol 2013; 88: 201-206.
21. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012; 119: 569-572.
22. Such E, Cervera J, Costa D, Sole F, Vallespi T, Luno E et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011; 96: 375-383.
23. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425.
24. Thol F, Kade S, Schlarmann C, Loffeld P, Morgan M, Krauter J et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012; 119: 3578-3584.
25. Bejar R, Lord A, Stevenson K, Bar-Natan M, Perez-Ladaga A, Zaneveld J et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 2014; 124: 2705-2712.
26. Park S, Labopin M, Yakoub-Agha I, Delaunay J, Dhedin N, Deconinck E et al. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia (CMML): A report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Eur J Haematol 2013; 90: 355-364.